Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for...
Possible Long on break above the 50MA,
previous trade did not work out well
but willing to give it another go.
Stochastic has bottomed
MACD is crossing
Histogram ticking higher
Volume rising
Rsi also crossed Mid-point
Eyes on the Gap fill to $4.18 but $3.60 short term.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
Hello Traders!
The price of Mustang Bio Inc has jumped up this Friday after a brief consolidation period. The RSI has reliably spiked in time with the upwards jump and the MACD has seen a bullish cross and reversal. It seems very likely that the price will regain an upwards momentum and reach the previous resistance level.
Going long could be a great...
Friday brought a significant break from a 200 & 100 MA channel.
Possible Gap fill to $4.18
Major pivot target $4.85
RSI crossed mid point
MACD bullish cross and reversal.
Histogram bullish above Zero-line
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, I previously predicted you should shorten $MBIO at $4.02. That was too conservative a bit, but you could have invested in higher growth stocks between then and now, as the most important thing is growth in the shortest time...
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for...
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for...
First off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, here is my analysis. Previous wave correlations point that MBIO is on the next wave of a breakout as the previous waves. Many analyst are ranking it a strong buy, and I even decided to replace my ALGN position (which I still...
Mustang Bio (NASDAQ:MBIO) is up 8.6% after hours following an bullish initiation at Overweight by Cantor, setting a $7s price target, implying 108% upside from today's close. This price target is actually considerable lower that the previous average of $19.50.
COMPANY PROFILE
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the...
NASDAQ:MBIO
Mustang Bio Inc
Stock - NASDAQ (USA)
Tested main volume after that we go up.
Profit:Risk = 3:1
---
Buy = $5.97
Take Profit = $8.50
Stop Loss = $5.04
------
Take Profit = +42.38%
Stop Loss = -15.58%
Mustang BIo had a very eventful day, after a initial 270% pump on the open it then dumped 45% of those gains quite quickly. If there new treatment gets FDA approval this stock will rocket higher but until then it is a no touch for us, if anything its a possible short.
